Published in Nat Med on December 01, 1997
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A (2006) 3.70
Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr (2014) 2.07
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol (2010) 2.04
CNTF receptor subunit α as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation. J Neurosurg (2012) 1.99
Immunotoxins for targeted cancer therapy. AAPS J (2006) 1.86
The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta (2011) 1.64
Entry of ricin and Shiga toxin into cells: molecular mechanisms and medical perspectives. EMBO J (2000) 1.60
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Immunotherapeutic approaches for glioma. Crit Rev Immunol (2009) 1.55
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin. Clin Exp Immunol (2004) 1.54
Act locally, think globally. Nat Med (1997) 1.43
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol (2007) 1.39
The intracellular trafficking pathway of transferrin. Biochim Biophys Acta (2011) 1.36
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A (2000) 1.32
Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother (2009) 1.28
An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids (2012) 1.25
Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg (2007) 1.24
The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry (2012) 1.24
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
Advances in anticancer immunotoxin therapy. Oncologist (2015) 1.22
Novel drug delivery strategies in neuro-oncology. Neurotherapeutics (2009) 1.21
Immunotherapy of malignant brain tumors. Immunol Rev (2008) 1.20
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A (2002) 1.19
Effect of ependymal and pial surfaces on convection-enhanced delivery. J Neurosurg (2008) 1.17
Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem (2005) 1.09
Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics (2009) 1.08
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 1.02
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol (2011) 0.99
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol (2005) 0.98
Gene therapy and targeted toxins for glioma. Curr Gene Ther (2011) 0.97
Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol (2008) 0.96
Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. Cancer Res (2010) 0.95
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones. Clin Exp Immunol (2001) 0.94
Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res (2014) 0.92
Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol (2012) 0.91
DTI-015 produces cures in T9 gliosarcoma. Neoplasia (2003) 0.91
A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature. J Neurooncol (2010) 0.91
Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol (2011) 0.90
Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg (2005) 0.90
Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts (2012) 0.90
Polymeric drug delivery for the treatment of glioblastoma. Neuro Oncol (2015) 0.90
Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol (2013) 0.88
Extraocular muscle force generation after ricin-mAb35 injection: implications for strabismus treatment. J AAPOS (2003) 0.88
Bioengineering strategies for designing targeted cancer therapies. Adv Cancer Res (2013) 0.86
Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol (2015) 0.85
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM? Cancers (Basel) (2013) 0.85
Dynamic contrast-enhanced MRI of Gd-albumin delivery to the rat hippocampus in vivo by convection-enhanced delivery. J Neurosci Methods (2012) 0.84
Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia (2003) 0.83
The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) (2011) 0.83
Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int (2015) 0.82
Comparison of pulsed versus continuous convective flow for central nervous system tissue perfusion: laboratory investigation. J Neurosurg (2012) 0.82
Molecular therapies for malignant glioma. Wien Med Wochenschr (2006) 0.81
Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Childs Nerv Syst (2010) 0.81
Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl Oncol (2010) 0.80
Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med (2012) 0.80
Transcriptional targeting of glioblastoma by diphtheria toxin-A driven by both H19 and IGF2-P4 promoters. Int J Clin Exp Med (2012) 0.80
Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J Drug Deliv (2013) 0.80
Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study. J Transl Med (2015) 0.79
Co-opting biology to deliver drugs. Biotechnol Bioeng (2014) 0.79
Glioblastoma multiforme--treating a deadly tumor with both strands of RNA. PLoS Med (2005) 0.78
Receptor-mediated uptake of an extracellular Bcl-x(L) fusion protein inhibits apoptosis. Proc Natl Acad Sci U S A (1999) 0.78
Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer. Mol Cancer (2014) 0.78
Convection-enhanced drug delivery for gliomas. Surg Neurol Int (2015) 0.78
Preparation and biocompatibility study of in situ forming polymer implants in rat brains. J Mater Sci Mater Med (2011) 0.78
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med Chem (2011) 0.77
Immunotoxins: a promising treatment modality for metastatic melanoma? Ochsner J (2010) 0.77
Novel therapeutic delivery approaches in development for pediatric gliomas. CNS Oncol (2013) 0.77
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier. Curr Pharm Des (2016) 0.76
Ephs and Ephrins in malignant gliomas. Growth Factors (2014) 0.76
Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg (2016) 0.76
Convection-enhanced Delivery of Therapeutics for Malignant Gliomas. Neurol Med Chir (Tokyo) (2016) 0.75
Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors. Int J Mol Sci (2017) 0.75
Clinical development of experimental therapies for malignant glioma. Sultan Qaboos Univ Med J (2011) 0.75
Neurological surgery at the National Institutes of Health. World Neurosurg (2010) 0.75
Convection-Enhanced Delivery. Neurotherapeutics (2017) 0.75
Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget (2016) 0.75
Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. PLoS One (2017) 0.75
Anticancer effects of the microbiome and its products. Nat Rev Microbiol (2017) 0.75
The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell (2001) 10.33
Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol (1997) 9.18
Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A (1997) 7.25
Structure of Bax: coregulation of dimer formation and intracellular localization. Cell (2000) 7.00
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem (1997) 5.95
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 5.47
Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J (1999) 5.10
Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem (1998) 4.71
Elucidating the pathophysiology of syringomyelia. J Neurosurg (1999) 4.43
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ (2003) 3.75
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol (2001) 3.09
Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol (2001) 2.86
In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res (1993) 2.74
Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest (1993) 2.42
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med (1997) 2.39
Bax, but not Bcl-xL, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations. Proc Natl Acad Sci U S A (1999) 2.32
Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction. Nat Biotechnol (1999) 2.22
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res (1992) 2.17
A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med (1997) 2.15
High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol (1994) 2.01
The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison. Ann Intern Med (1994) 2.00
Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg (1999) 1.97
Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg (1995) 1.94
Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. Am J Physiol (1993) 1.93
Spinal arteriovenous malformations: a comparison of dural arteriovenous fistulas and intradural AVM's in 81 patients. J Neurosurg (1987) 1.92
The role of free radicals and p53 in neuron apoptosis in vivo. J Neurosci (1995) 1.79
Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med (1994) 1.78
Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol (1999) 1.77
Reversible acute and subacute myelopathy in patients with dural arteriovenous fistulas. Foix-Alajouanine syndrome reconsidered. J Neurosurg (1989) 1.75
Brief report: relief of spinal cord compression from vertebral hemangioma by intralesional injection of absolute ethanol. N Engl J Med (1994) 1.75
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J Cell Biol (2000) 1.74
Which came first, the cytochrome c release or the mitochondrial fission? Cell Death Differ (2006) 1.71
Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med (1994) 1.70
Organelle-specific Isozymes of Aspartate-alpha-Ketoglutarate Transaminase in Spinach Leaves. Plant Physiol (1976) 1.64
Multiple pituitary adenomas in Cushing's disease. J Neurosurg (2000) 1.63
Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest (1996) 1.63
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem (1993) 1.60
Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates. J Neurosurg (1999) 1.59
Symptomatic vertebral hemangiomas: treatment by means of direct intralesional injection of ethanol. Radiology (2000) 1.58
In situ labeling of granule cells for apoptosis-associated DNA fragmentation reveals different mechanisms of cell loss in developing cerebellum. Neuron (1993) 1.58
Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology (2006) 1.57
Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol (1996) 1.57
Surgical interruption of intradural draining vein as curative treatment of spinal dural arteriovenous fistulas. J Neurosurg (1995) 1.56
Tumor devascularization by intratumoral ethanol injection during surgery. Technical note. J Neurosurg (1998) 1.55
Bilateral sampling of the internal jugular vein to distinguish between mechanisms of adrenocorticotropic hormone-dependent Cushing syndrome. Ann Intern Med (1998) 1.54
Direct convective delivery of macromolecules to the spinal cord. J Neurosurg (1998) 1.53
Selective excision of adenomas originating in or extending into the pituitary stalk with preservation of pituitary function. J Neurosurg (1997) 1.49
Extrapituitary parasellar microadenoma in Cushing's disease. J Clin Endocrinol Metab (1999) 1.49
The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism. Histochemical and behavioral studies. J Neurosurg (1990) 1.48
Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. J Neurosurg (1991) 1.46
Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients. Ann Intern Med (1989) 1.46
Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther (1993) 1.44
The mannose 6-phosphate receptor of Chinese Hamster ovary cells. Isolation of mutants with altered receptors. J Biol Chem (1981) 1.42
The role of 2'-5' oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ (1998) 1.41
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci (1986) 1.39
Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc Natl Acad Sci U S A (1980) 1.36
The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med (1984) 1.36
Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain. J Neuropathol Exp Neurol (1999) 1.35
Direct convective delivery of macromolecules to peripheral nerves. J Neurosurg (1998) 1.35
Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther (1997) 1.33
Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg (1997) 1.32
Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res (1997) 1.31
Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution. J Biol Chem (1982) 1.31
Bcl-2 family interaction with the mitochondrial morphogenesis machinery. Cell Death Differ (2010) 1.31
The 2-5A system in viral infection and apoptosis. Biomed Pharmacother (1998) 1.30
Neurosurgical implications of Carney complex. J Neurosurg (2000) 1.30
Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene (2011) 1.28
Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg (1989) 1.27
Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science (1987) 1.25
Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol (2001) 1.23
Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential. Cell Death Differ (2001) 1.22
Management of the ectopic ACTH syndrome due to thoracic carcinoids. Ann Thorac Surg (1990) 1.20
Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J Biol Chem (1992) 1.18
The C-terminal helix of Bcl-x(L) mediates Bax retrotranslocation from the mitochondria. Cell Death Differ (2012) 1.15
Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor. J Clin Endocrinol Metab (2001) 1.14
Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab (1999) 1.14
Successful treatment of a group of spinal cord arteriovenous malformations by interruption of dural fistula. J Neurosurg (1983) 1.13
Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy. Immunol Rev (1982) 1.13
Resection of suprasellar tumors by using a modified transsphenoidal approach. Report of four cases. J Neurosurg (2000) 1.13
Treatment of cranial dural arteriovenous fistulae by interruption of leptomeningeal venous drainage. J Neurosurg (1994) 1.12
Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone. J Neurosurg (1987) 1.12
A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab (1994) 1.12
Evolution of VHL tumourigenesis in nerve root tissue. J Pathol (2006) 1.11
Identification and characterization of a monoclonal antibody recognizing a galactose-binding domain of the toxin ricin. J Immunol (1987) 1.09
Early repeat surgery for persistent Cushing's disease. J Neurosurg (1994) 1.09
Cell surface and intracellular functions for ricin galactose binding. J Biol Chem (1992) 1.08
A study of the intracellular routing of cytotoxic ribonucleases. J Biol Chem (1995) 1.08
Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease. Lancet (1984) 1.07
Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg (1996) 1.06
Hybridoma cells containing intracellular anti-ricin antibodies show ricin meets secretory antibody before entering the cytosol. J Biol Chem (1987) 1.06
Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. J Neurosurg (1998) 1.06
Allelic loss on chromosome 11 in hereditary and sporadic tumors related to familial multiple endocrine neoplasia type 1. Cancer Res (1991) 1.06
Spinal cord swelling preceding syrinx development. Case report. J Neurosurg (2000) 1.06
Usefulness of inferior petrosal sinus venous endocrine markers in Cushing's disease. J Neurosurg (1988) 1.06